Combining the aforementioned positive features of a CD276-CAR, targeting a tumor-specific antigen, with the NK-92 cell line and its strong resilience to influences exerted by the TME generates a powerful cellular product that can be easily manufactured under GMP guidelines as a readily available, “off-the-shelf” treatment option for melanoma and other solid tumors. This evidence concerns the gene CD276 and neoplasm.